Company intelligence / Profile preview

CellVoyant

Bristol, England, United Kingdomcellvoyant.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

CellVoyant has developed an AI-first platform leveraging live-cell imaging and deep learning to predict, optimize, and control stem cell differentiation for scalable manufacturing of any desired cell or tissue. The company’s technology aims to accelerate the development of novel stem cell-based therapies for chronic diseases. No clinical trial results are available yet.

Therapeutic areas: Other
Modalities: Stem cell-based therapiesinduced pluripotent stem cells (iPSCs)
Industry: Biotech

Partnerships

Strategic partnerships with leading institutions in healthcare industry mentioned but no specific names provided; supported by investors linked to DeepMind, Exscientia, Recursion, Wayve; founder/CEO of Abcam also supports the company.

Beyond the preview

Go deeper on CellVoyant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellVoyant.

Explore the full profile